Over the last 15 years, we have, within CREATE Health, developed a robust, multiplexed antibody microarray platform where hundreds of serum protein can be screened in a few days. These antibody microarrays are one of the most advanced affinity proteomic tools available, as proven by over 20 clinical studies (1-3). The general conclusions from analyzing several different complex disease indications, such as cancer, autoimmunity, infections etc., is that 20-25 proteins in serum can be used as a biomarker “signature” to discriminate different complex disease indications.
- Borrebaeck CAK (2017) Precision diagnostics: Moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer 17(3):199-204
- Wingren C, Sandström A, Segersvärd R, Carlsson A, Andersson R, Löhr M, Borrebaeck CAK (2012) Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res 72, 2481-2490.
- Borrebaeck CAK (2012) Viewpoint in Clinical Proteomics – When will proteomics deliver clinically useful information? Clin Proteomics 6, 343-345.
- Carlsson A, Wingren C, Kristensson M, Rose C, Fernö M, Olsson H, Jernström H, Ek S, Gustavsson E, Ingvar C, Ohlsson M, Peterson C, Borrebaeck CAK (2011) Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci 108, 14252-14257.